Vizimpro 45 mg Alternative – Dacocent (Dacomitinib) 45 mg Tablet | Incepta Pharmaceuticals

Product Overview

Dacocent 45 mg Tablet is manufactured by Incepta Pharmaceuticals Ltd. It contains Dacomitinib 45 mg, an irreversible EGFR/HER family kinase inhibitor. Vizimpro by Pfizer is a reference brand for dacomitinib; shared ingredients do not prove bioequivalence or interchangeability.

Reference Brand Comparison – Dacocent vs Vizimpro

Both are associated with dacomitinib 45 mg tablets, but regulatory approvals, excipients and product-specific evidence must be checked before substitution.

Composition

Each film-coated tablet contains dacomitinib monohydrate equivalent to dacomitinib 45 mg. Manufacturer: Incepta Pharmaceuticals Ltd., Bangladesh. Pack: 10 tablets.

Therapeutic Uses and Indications

Dacomitinib is indicated for selected metastatic non-small cell lung cancer with EGFR exon 19 deletion or exon 21 L858R substitution mutations, subject to local approval and testing.

Mechanism of Action

Dacomitinib irreversibly inhibits EGFR/HER family tyrosine kinase signaling, including selected activating EGFR mutations.

Dosage and Administration

Only use the regimen prescribed by an oncologist. The 45 mg product strength does not replace individual dosing advice. Follow the official leaflet for food, missed doses and dose adjustments.

Contraindications and Warnings

Review the authorized label for contraindications. Serious risks include diarrhea, dermatologic reactions, interstitial lung disease and fetal harm. Liver and other monitoring may be needed.

Possible Side Effects

Diarrhea, rash and skin changes may occur. Seek medical attention for severe diarrhea, breathing difficulty or serious skin reactions.

Drug Interactions

Proton pump inhibitors can reduce dacomitinib exposure. H2 blockers and CYP2D6 substrates may require special management. Review all medicines with a clinician.

Pregnancy and Breastfeeding

Dacomitinib can cause fetal harm. Follow the official contraception and breastfeeding restrictions.

Storage

Store below 30°C, protected from light and away from children, following the actual pack.

Manufacturer and Reference Brand

Brand: Dacocent. Generic: Dacomitinib. Strength: 45 mg. Manufacturer: Incepta Pharmaceuticals Ltd. Reference: Vizimpro (Pfizer).

FAQs

Is Dacocent the same as Vizimpro?

Both contain dacomitinib, but automatic interchangeability is not established.

Is Dacocent used for lung cancer?

Dacomitinib is used for specific EGFR-mutated NSCLC under specialist supervision.

Medical Disclaimer

Educational information only. Consult the official manufacturer label and a qualified oncologist.

Official source: Incepta Dacocent product information.